A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).

Seth A. Wander,Mark L. Zangardi,Andrzej Niemierko,Avinash Kambadakone,Leslie Sl Kim,Jing Xi,Apurva Pandey,Laura Spring,Casey Stein,Dejan Juric,Irene Kuter,Beverly Moy,Therese M. Mulvey,Neelima Vidula,Steven J. Isakoff,Megan Yuen,Adam Brufsky,Cynthia X. Ma,Joyce O'Shaughnessy,Aditya Bardia

A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).

2019

1057Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are widely used for pts with HR+/HER2- MBC. The MONARCH-1 trial of abemaciclib monotherapy in pre-treated pts demonstrated a median ...

Keywords:

Hormone receptor
Palbociclib
Abemaciclib
Oncology
Pathology
Kinase
Medicine
Metastatic breast cancer
Internal medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations